Blog

Company News

Industry Trends

Laws Regulations

All Categories >

21

2022-12

Hycells Bio | Dedicated to Research on Cell and Animal Models for Drug Development

Shanghai Hycells Biotechnology Co., Ltd. has long been deeply engaged in the cell and gene therapy segment of large-molecule drug development. Since its inception, the company has leveraged a solid customer base and years of accumulated R&D service expertise to establish robust technological barriers, delivering highly satisfactory services that have earned a strong reputation among new-drug R&D enterprises. As a result, it has forged long-term, stable partnerships with numerous leading CROs, cell therapy companies, and gene therapy firms. Moving forward, we will continue to optimize our clinical, technical, and business management systems as well as our service processes, thereby providing collaborative partners in the biopharmaceutical sector with services that meet even higher standards.

2022-12-21

He Yousheng

19

2022-12

To Our Original Aspiration, Embarking on a New Journey | Hycells Biological Relocates to New Headquarters

2022 was an extraordinary year for everyone. Although the pandemic restricted our movements, it only intensified our collective commitment to safeguarding human life and health. In November 2022, Hycells Biotechnology turned a new, milestone chapter in its history by relocating to a brand-new facility—marking a significant leap forward in the company’s manufacturing and R&D capabilities and providing a powerful boost to its sustained growth. Thanks to the concerted efforts of colleagues across all departments, we officially moved into our new premises on November 21, 2022.

2022-12-19

He Yousheng
< 1...12131415 >